Masayuki Nakamura

Prof. Masayuki Nakamura


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
ATAtsushi Takata
Atsushi Takata
MKMaiko Kato
Maiko Kato
MNMasayuki Nakamura
Masayuki Nakamura
TYTakeo Yoshikawa
Takeo Yoshikawa
SKShigenobu Kanba
Shigenobu Kanba
TKTadafumi Kato
Tadafumi Kato
Background: Whole-exome sequencing using next-generation technologies has been previously demonstrated to be able to detect rare disease-causing variants. Progressive external ophthalmoplegia (PEO) is an inherited mitochondrial disease that follows either autosomal dominant or recessive forms of inheritance (adPEO or arPEO). AdPEO is a genetically heterogeneous disease and several genes, including POLG1 and C10orf2/Twinkle, have been identified as responsible genes. On the other hand, POLG1 was the only established gene causing arPEO with mitochondrial DNA deletions. We previously reported a case of PEO with unidentified genetic etiology. The patient was born of a first-cousin marriage. Therefore, the recessive form of inheritance was suspected. Results: To identify the disease-causing variant in this patient, we subjected the patient's DNA to whole-exome sequencing and narrowed down the candidate variants using public data and runs of homozygosity analysis. A total of 35 novel, putatively functional variants were detected in the homozygous segments. When we sorted these variants by the conservation score, a novel missense variant in RRM2B, whose heterozygous rare variant had been known to cause adPEO, was ranked at the top. The list of novel, putatively functional variants did not contain any other variant in genes encoding mitochondrial proteins registered in MitoCarta. Conclusions: Exome sequencing efficiently and effectively identified a novel, homozygous missense variant in RRM2B, which was strongly suggested to be causative for arPEO. The findings in this study indicate arPEO to be a genetically heterogeneous disorder, as is the case for adPEO.

1 September 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ONOmi Nagata
Omi Nagata
MNMasayuki Nakamura
Masayuki Nakamura
HSHitoshi Sakimoto
Hitoshi Sakimoto
YUYuka Urata
Yuka Urata
NSNatsuki Sasaki
Natsuki Sasaki
ASAkira Sano
Akira Sano

1 June 2019 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
YUYuka Urata
Yuka Urata
MNMasayuki Nakamura
Masayuki Nakamura
NSNatsuki Sasaki
Natsuki Sasaki
NSNari Shiokawa
Nari Shiokawa
YNYoshiaki Nishida
Yoshiaki Nishida
ASAkira Sano
Akira Sano
Objective To identify XK pathologic mutations in 6 patients with suspected McLeod syndrome (MLS) and a possible interaction between the chorea-acanthocytosis (ChAc)- and MLS-responsible proteins: chorein and XK protein. Methods Erythrocyte membrane proteins from patients with suspected MLS and patients with ChAc, ChAc mutant carriers, and normal controls were analyzed by XK and chorein immunoblotting. We performed mutation analysis and XK immunoblotting to molecularly diagnose the patients with suspected MLS. Lysates of cultured cells were co-immunoprecipitated with anti-XK and anti-chorein antibodies. Results All suspected MLS cases were molecularly diagnosed with MLS, and novel mutations were identified. The average onset age was 46.8 ± 8 years, which was older than that of the patients with ChAc. The immunoblot analysis revealed remarkably reduced chorein immunoreactivity in all patients with MLS. The immunoprecipitation analysis indicated a direct or indirect chorein-XK interaction. Conclusions In this study, XK pathogenic mutations were identified in all 6 MLS cases, including novel mutations. Chorein immunoreactions were significantly reduced in MLS erythrocyte membranes. In addition, we demonstrated a possible interaction between the chorein and XK protein via molecular analysis. The reduction in chorein expression is similar to that between Kell antigens and XK protein, although the chorein-XK interaction is a possibly noncovalent binding unlike the covalent Kell-XK complex. Our results suggest that reduced chorein levels following lack of XK protein are possibly associated with molecular pathogenesis in MLS.

1 January 1998
Verified
Journal Article
Closed access
PSPhontip Sirivan
Phontip Sirivan
MOMakiko Obayashi
Makiko Obayashi
MNMasayuki Nakamura
Masayuki Nakamura
UTUrasri Tantaswasdi
Urasri Tantaswasdi
KTKazuaki Takehara
Kazuaki Takehara
By using primers (AL18F2 and AL18R2) designed from goose parvovirus (GPV) strain IHC, an 806-bp band was amplified by polymerase chain reaction (PCR) from all o...

1 June 2019 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
YNYoshiaki Nishida
Yoshiaki Nishida
MNMasayuki Nakamura
Masayuki Nakamura
YUYuka Urata
Yuka Urata
KKKei Kasamo
Kei Kasamo
HHHanae Hiwatashi
Hanae Hiwatashi
ASAkira Sano
Akira Sano
Objective To identify mutations in vacuolar protein sorting 13A (VPS13A) for Japanese patients with suspected chorea-acanthocytosis (ChAc). Methods We performed a comprehensive mutation screen, including sequencing and copy number variation (CNV) analysis of the VPS13A gene, and chorein Western blotting of erythrocyte ghosts. As the results of the analysis, 17 patients were molecularly diagnosed with ChAc. In addition, we investigated the distribution of VPS13A gene mutations and clinical symptoms in a total of 39 molecularly diagnosed Japanese patients with ChAc, including 22 previously reported cases. Results We identified 11 novel pathogenic mutations, including 1 novel CNV. Excluding 5 patients with the unknown symptoms, 97.1% of patients displayed various neuropsychiatric symptoms or forms of cognitive dysfunction during the course of disease. The patients carrying the 2 major mutations representing over half of the mutations, exon 60–61 deletion and exon 37 c.4411C>T (R1471X), were localized in western Japan. Conclusions We identified 13 different mutations in VPS13A, including 11 novel mutations, and verified the clinical manifestations in 39 Japanese patients with ChAc.

1 March 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HSHitoshi Sakimoto
Hitoshi Sakimoto
MNMasayuki Nakamura
Masayuki Nakamura
ONOmi Nagata
Omi Nagata
IYIzumi Yokoyama
Izumi Yokoyama
ASAkira Sano
Akira Sano